Skip to content
TrialScanner

NCT05227820

Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia

Phase 2CompletedBIVICollaborator

Registry record

Lead sponsor
Neurological Associates of West Los Angeles
Conditions
Alzheimer Disease
Primary completion
Jul 20, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05227820 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05227820: Insulin-Sensitizing Anti-Infl... | TrialScanner